Heska Corporation (HSKA)
(Delayed Data from NSDQ)
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Pfizer (PFE) Presents Favorable Data on Leukemia Candidate
by Zacks Equity Research
Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).
Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug
by Zacks Equity Research
Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures.
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in pediatric patients.
Achillion, J&J to Initiate Phase IIb Study on HCV Combo
by Zacks Equity Research
Achillion Pharmaceuticals, Inc. (ACHN) announced the initiation of patient dosing in a global phase IIb on JNJ-4178 ??? a triple combination of AL-335, odalasvir (also known as ACH-3102) and J&J's Olysio (simeprevir).
Ultragenyx (RARE) Reports Positive Phase II Study on UX007
by Zacks Equity Research
Ultragenyx (RARE) announced positive data from a phase II study on UX007 for the treatment of patients with long-chain fatty acid oxidation disorder (LC-FAOD).
Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced that it is expanding its sales force to reach primary care physicians.
Amicus Provides Regulatory Update on Fabry Disease Drug
by Zacks Equity Research
Amicus Therapeutics, Inc. (FOLD) issued an update on the regulatory pathway for migalastat for the treatment of Fabry disease in the U.S.
Mallinckrodt (MNK) Tops Q4 Earnings on Solid Sales Growth
by Zacks Equity Research
Mallinckrodt Public Limited Company (MNK) reported adjusted earnings of $2.04 per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016), beating the Zacks Consensus Estimate of $1.98.
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte
Zacks.com featured highlights: Heska, Teradyne, Nxstage Medical, Unifi and Rollins
by Zacks Equity Research
Zacks.com featured highlights: Heska, Teradyne, Nxstage Medical, Unifi and Rollins
Top Ranked Momentum Stocks to Buy for November 4th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, November 4th:
New Strong Buy Stocks for June 2nd
by Swarup Gupta
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday